Stockscreener 앱 받기
1.05
2.78%
-0.03
시간 외 거래:
1.04
-0.01
-0.95%
전일 마감가:
$1.08
열려 있는:
$1.06
하루 거래량:
61,949
Relative Volume:
0.18
시가총액:
$44.92M
수익:
$18.89M
순이익/손실:
$-20.44M
주가수익비율:
-1.333
EPS:
-0.7877
순현금흐름:
$-46.69M
1주 성능:
-8.70%
1개월 성능:
-6.25%
6개월 성능:
-3.67%
1년 성능:
-67.99%
1일 변동 폭
$1.04
$1.08
1주일 범위
$1.03
$1.19
52주 변동 폭
$0.50
$3.39
Elutia Inc Stock (ELUT) Company Profile
명칭
Elutia Inc
전화
240-247-1143
주소
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
1.05 | 46.21M | 18.89M | -20.44M | -46.69M | -0.7877 |
|
ABT
Abbott Laboratories
|
107.19 | 188.52B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
339.76 | 132.34B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.87 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.89 | 105.77B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
82.46 | 47.98B | 6.07B | 1.06B | 1.34B | 1.8063 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-02 | 개시 | Cowen | Outperform |
| 2020-11-02 | 개시 | Piper Sandler | Overweight |
| 2020-11-02 | 개시 | Truist | Buy |
Elutia Inc 주식(ELUT)의 최신 뉴스
Elutia Inc. (NASDAQ:ELUT) Q4 2025 earnings call transcript - MSN
Elutia (ELUT) Q4 2025 Earnings Call Transcript - AOL.com
Forecast Cut: Is Elutia Inc subject to activist investor interest2026 Earnings Surprises & Low Risk High Reward Ideas - baoquankhu1.vn
Aug Technicals: Is Elutia Inc subject to activist investor interest2026 Price Momentum & Weekly Momentum Stock Picks - baoquankhu1.vn
Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19 - Bitget
Elutia details tech to address infections in breast reconstruction - Stock Titan
Elutia Warns of Ongoing Nasdaq Delisting Risk Despite Recent Compliance Win - TipRanks
Elutia (ELUT) Grants Stock Options to New Hires - GuruFocus
Elutia announces grants of inducement awards - TipRanks
Exit Recap: Is Elutia Inc subject to activist investor interest2026 Market Mood & Detailed Earnings Play Strategies - baoquankhu1.vn
Elutia 2025 10-K: Revenue $12.3M, EPS (cont. ops) $(15.871)M - TradingView
Elutia (NASDAQ: ELUT) pivots to drug‑eluting biomatrix after asset divestitures - Stock Titan
Achieving Micron-Level Tolerances: CAD Optimization for Sub-10µm 3D Printing - AOL.com
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Bitget
Elutia markets another product for sale as it pivots to breast reconstruction infection prevention - The Business Journals
Elutia Announces Grants of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
[Form 4] ELUTIA INC. Insider Trading Activity - Stock Titan
Elutia (ELUT) CEO receives stock from RSU vesting while shares withheld for taxes - Stock Titan
Elutia Q4 2025 slides: $88M sale funds pivot to breast reconstruction - Investing.com Australia
Elutia Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ELUT) 2026-03-12 - Seeking Alpha
Elutia Reports Strong 2025 Financial Results, Advances NXT-41x for Breast Cancer Surgery, and Closes $88M BioEnvelope Sale to Boston Scientific - Minichart
Elutia Inc (ELUT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Moves Amid ... By GuruFocus - Investing.com Canada
Elutia Inc (ELUT) Q4 2025 Earnings Call Highlights: Revenue Grow - GuruFocus
Elutia outlines launch timeline for NXT-41x in $1.5B breast reconstruction market while strengthening leadership team - MSN
Elutia Q4 2025 slides: $88M sale funds pivot to breast reconstruction By Investing.com - Investing.com South Africa
Elutia Inc. (ELUT) Q4 2025 Earnings Call Transcript Summary - 富途牛牛
Elutia Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process - Bitget
Earnings call transcript: Elutia Q4 2025 beats forecasts, stock steady - Investing.com Australia
Earnings call transcript: Elutia Q4 2025 beats forecasts, stock steady By Investing.com - Investing.com India
Elutia Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Elutia earnings beat by $1.60, revenue topped estimates - Investing.com Canada
Elutia reports $3.3M Q4 revenue, $70.8M net income on BioEnvelope sale; $44.4M year-end cash - TradingView
ELUTIA ($ELUT) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
Elutia Q4 revenue rises on higher cardiovascular product sales - TradingView
ELUT: Q4 2025 revenue up 16% year-over-year; focus shifts to NXT-41x for breast reconstruction - TradingView
ELUT: Q4 net income soared to $70.8M on BioEnvelope sale, with NXT-41x FDA process underway - TradingView
Elutia Inc. Adopts 2026 Inducement Award Plan and Files Form 8-K Disclosure - Minichart
Exploring Elutia's Earnings Expectations - Benzinga
Elutia Inc (ELUT) Q4 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
Elutia Adopts 2026 Inducement Equity Award Plan - TipRanks
Elutia (NASDAQ: ELUT) sets 2026 inducement plan for 2,000,000 share awards - Stock Titan
Elutia Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Elutia Regains Full Nasdaq Compliance, Strengthening Listing Status - The Globe and Mail
Elutia (ELUT) Expected to Announce Earnings on Wednesday - MarketBeat
Elutia regains compliance with Nasdaq listing requirements - Investing.com Australia
Elutia regains compliance with Nasdaq listing requirements By Investing.com - Investing.com Canada
Elutia regains Nasdaq compliance after meeting minimum bid price and MVLS - TradingView
Elutia Inc (ELUT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.85%
1.86%
자본화:
|
볼륨(24시간):